Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant
Phase: Phase 1
Diagnosis: Hematopoietic Stem Cell Transplant, Non-Hodgkin's Lymphoma
NCT ID: NCT00697684
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 07-384
This study will examine the safety of clofarabine, TLI and ATG as a reduced conditioning regimen prior to allogeneic transplantation. The impact of the conditioning regimen on the presence of the circulating regulatory as compared to activated T cell populations will be assessed.The recovery of DC populations post-transplant will be examined, along with the effect of the regimen on disease free and overall survival.
Beth-Israel Deaconess Medical Center, Massachusetts General Hospital, Dana-Farber Cancer Institute
Thomas Spitzer, MD,
Massachusetts General Hospital
David Avigan, MD,
Beth Israel Deaconess Medical Center
Massachusetts General Hospital:
Cancer Trials Call Center, 877-789-6100
Beth-Israel Deaconess Medical Center:
Cancer Trials Call Center, 617-667-3060
1. Patients with a)acute myeloid leukemia exclusive of patients in first complete
remission with good risk cytogenetics (translocation 8,21,translocation 15, 17 or
inversion 16); B)myelodysplastic syndrome; c)acute lymphocytic leukemia exclusive of
patients in first remission without negative prognostic markers; d) relapsed or
refractory nonHodgkin's lymphoma or Hodgkin's disease; e)relapsed or refractory
multiple myeloma or f)relapsed or refractory chronic lymphocytic leukemia.
2. Patients who are considered appropriate for reduced intensity transplantation must
present with at least one of the following: A. Age over 50 B. History of a prior
hematopoietic stem cell transplant C. Patient with compromised organ function or
comorbid conditioning such that a standard ablative transplant would be considered
3. Patients will have a related or unrelated donor matched at 5/6 or 6/6 HLA loci.
4. Patients must be greater than or equal to 18 years old, and younger than or equal to
70 years old to participate in the study.
5. Patients must have ECOG performance status of 0-2
6. Pulmonary function tests demonstrate DLCO (adjusted for Hgb)>50% predicted
7. Cardiac ejection fraction >40%
- Bilirubin less than or equal to 1.5mg/dL x ULN
- AST/ALT/Alkaline Phosphatase less than or equal to 2.5x ULN
- Serum creatinine less than or equal to 1.0mg/dL; if serum creatinine > 1.0MG/dL,
then the estimated glomerular filtration rate (GFR) must be >60mL/min/1.73m^2 as
calculated by the Modification of Diet in Renal Disease equation where Predicted
GRF (ml/min/1.73m^2)=186x (serum creatinine)^1.154x(age in years)^-0.023x(0.742
if patient is female) x (1.212 if patient is black)
9. Patients with serologic evidence of hepatitis B or C exposure will undergo liver
biopsy to assess for presence of active hepatitis or fibrosis and quantification of
risk of proceeding with transplant.
10. All patients must be capable of understanding the investigational nature, potential
risks and benefits of the study, and able to provide valid informed consent. All patients
must be informed of the investigational nature of this study and must give written informed
consent in accordance with institutional and federal guidelines.
11. Female patients of childbearing potential must have a negative serum pregnancy test
within 2 weeks prior to enrollment.
12. Male and female patients must use an effective contraceptive method during the study
and for a minimum of 6 months after study treatment
1. Patients who are HIV+ will be excluded.
2. Patients must not have serious intercurrent illness such as uncontrolled systemic
infection or significant organ compromise which significantly increases the risk of
undergoing allogeneic transplantation.
3. Pregnant and lactating women will be excluded.